1-11 of 11
Andrew K McMillan, FRCP
Close
Sort by
Journal Articles

Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial

Catherine Diefenbach, MD, Brad S. Kahl, MD, Lalita Banerjee, FRCPath, Andrew K McMillan, FRCP, Fiona Miall, MD FRCPath, MRCP, BMBS, Javier Briones, MD PhD, Raul Cordoba, MD PhD, Jamie Hirata, PharmD, YiMeng Chang, MSc, Lisa Musick, PharmD, Pau Abrisqueta, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 126.
https://doi.org/10.1182/blood-2019-123669
Published: 2019
Journal Articles

Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14

Anthony V. Moorman, Ellie Butler, Emilio Barretta, Amy A. Kirkwood, MSc, Claire Schwab, PhD, Thomas Creasey, MBBS, Daniel A. Leongamornlert, PhD, Elli Papaemmanuil, PhD, Pip Patrick, PhDMSc,MA, Laura Clifton-Hadley, PhDBSc, Bela Wrench, MBBS, MD MRCP, FRCPath, Tobias F Menne, MD PhD FRCPath, Andrew K McMillan, FRCP, Christine J. Harrison, PhD FRCPath, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, David I Marks, MBBS, PhD FRCPath, Adele K. Fielding, MBBS,PhDFRCP,FRCPath
Journal: Blood
Blood (2019) 134 (Supplement_1): 288.
https://doi.org/10.1182/blood-2019-123642
Published: 2019
Journal Articles

POLARGO: A Randomized Phase III Study Evaluating Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Had Received One or More Previous Therapies

Andrew K McMillan, FRCP, Matthew J Matasar, MD, Juan-Manuel Sancho, MD PhD, Andreas Viardot, MD PhD, Juana Hernandez, MD, Thomas Perretti, MD MSc, Corinne Haioun, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5317.
https://doi.org/10.1182/blood-2019-123673
Published: 2019
Journal Articles

Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study

Laurie H Sehn, MD, Matthew J Matasar, MD, Christopher R. Flowers, MD MS, Manali Kamdar, MD MD, Andrew K McMillan, FRCP, Mark Hertzberg, MD MBBS, PhD, Sarit Assouline, MD, Tae Min Kim, MD PhD, Won Seog Kim, MD PhD, Muhit Ozcan, MD, Brandon Croft, PharmD, Jamie Hirata, PharmD, Ji Cheng, PhD, Grace Ku, MD, Alex F. Herrera, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4081.
https://doi.org/10.1182/blood-2019-123449
Published: 2019
Journal Articles

Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials

Thomas Creasey, MBBS, Emilio Barretta, Amy A. Kirkwood, MSc, Claire Schwab, PhD, Pip Patrick, PhDMSc,MA, Laura Clifton-Hadley, PhDBSc, Bela Wrench, MBBS, MD MRCP, FRCPath, Tobias F Menne, MD PhD FRCPath, Andrew K McMillan, FRCP, Nicholas J. Morley, John A Snowden, BSc (Hons), MBChB, MD FRCP, FRCPath, Christine J. Harrison, PhD FRCPath, Daniel A. Leongamornlert, PhD, Elli Papaemmanuil, PhD, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, David I Marks, MBBS, PhD FRCPath, Adele K. Fielding, MBBS,PhDFRCP,FRCPath, Anthony V. Moorman
Journal: Blood
Blood (2019) 134 (Supplement_1): 2746.
https://doi.org/10.1182/blood-2019-124395
Published: 2019
Journal Articles

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

David I Marks, MBBS, PhD FRCPath, Amy A. Kirkwood, MSc, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, Melanie Aguiar, BSc, Katharine E Bailey, MBBS, FRCPath, MA, MRCP, Brendan Beaton, MD, Laura Clifton-Hadley, PhDBSc, Emma Lawrie, BSc, SooWah Lee, MSc, Andrew K McMillan, FRCP, Anthony V. Moorman, PhD, Rachel J. Mitchell, MSc, Pip Patrick, PhDMSc,MA, Tobias F Menne, MD PhD FRCPath, Paul Smith, Bela Wrench, MBBS, MD MRCP, FRCPath, Krisztina Zuborne Alapi, MSc, Adele K. Fielding, MBBS,PhDFRCP,FRCPath
Journal: Blood
Blood (2019) 134 (Supplement_1): 739.
https://doi.org/10.1182/blood-2019-123374
Published: 2019
Journal Articles

Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

Anna Santarsieri, MBBS, Katherine Sturgess, MA, MBBChir, MRCP, MSc, Pauline Brice, Tobias F Menne, MD PhD FRCPath, Wendy Osborne, MD, Thomas Creasey, MBBS, Kirit M. Ardeshna, MA, MD FRCP, FRCPath, Sarah Behan, Stephen Booth, MA,MBBChir,MRCP,FRCPath, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Kate Cwynarski, PhDMD, Sunil Iyengar, MD, Stephen G Jones, Deirdre O'Mahony, MD, Nicolas Martinez-Calle, MD MSc, Pamela McKay, MD, Sateesh K Nagumantry, BM BCh, John Rudge, MA, PhD, Nimish Shah, MD, Gwyneth Stafford, Alexander Sternberg, Benjamin J Uttenthal, MD PhD, Andrew K McMillan, FRCP, George A Follows, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1564.
https://doi.org/10.1182/blood-2019-125256
Published: 2019
Journal Articles

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Andrea Kuhnl, Claire Roddie, PhD MD, Nuria Martinez-Cibrian, Tobias F Menne, MD PhD FRCPath, Kim Linton, MBChB PhD, Sanne Lugthart, Sridhar Chaganti, MDPhDMRCP,FRCPath, Robin Sanderson, MRCP,FRCPath, Maria A V Marzolini, Jane Norman, MD, Wendy Osborne, MD, John Radford, Stephen Robinson, MBBS, PhD BSc, Ram Malladi, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Maeve A O'Reilly, MBBCHBAO, Muhammad Saif, MD, Geoff Shenton, Adrian Bloor, FRCPath, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, David A. Irvine, BSc, MBBChir, MRCP, FRCPath, PhD, Orla Stewart, Arzhang Ardavan, Kate Robinson, Antonio Pagliuca, MBBS, MA, FRCP, FRCPath, Kristian M Bowles, MBBS, PhD, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Rod Johnson, Andrew K McMillan, FRCP
Journal: Blood
Blood (2019) 134 (Supplement_1): 767.
https://doi.org/10.1182/blood-2019-124177
Published: 2019
Journal Articles

Kinetics of T-Cell Subset Reconstitution Following Bendamustine-Containing Therapy for Low-Grade Lymphoproliferative Disease; A Population Based Analysis

Sarah Hartley, MBBS, MRCP, Amy Beech, Catherine Griffiths, Faith Richardson, Helen Knight, Andrew K. McMillan, FRCP, Mark Bishton, Chris P Fox
Journal: Blood
Blood (2017) 130 (Supplement 1): 3586.
https://doi.org/10.1182/blood.V130.Suppl_1.3586.3586
Published: 2017
Journal Articles

Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study

Laurie H. Sehn, MDMPH, Alex F. Herrera, MD, Matthew J. Matasar, MD, Manali Kamdar, Andrew K. McMillan, FRCP, Tae Min Kim, Won Seog Kim, MD, Ph. D., Mark Hertzberg, MBBS, PhD, Muhit Ozcan, MD, Elicia Penuel, Ji Cheng, Jamie M. Hirata, Grace Ku, Christopher Flowers, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2821.
https://doi.org/10.1182/blood.V130.Suppl_1.2821.2821
Published: 2017
Journal Articles

Successful Salvage of Refractory Burkitts Lymphoma Using Maximum Intensity of the DA EPOCH-R Regimen—a Case Report

Andrew K. McMillan, FRCP, Sarah Hartley, MBBS, MRCP, Catherine Loughran, Mark Bishton, Eleanor James, Catherine Griffiths, Faith Richardson, Christopher P Fox, MBChB PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5229.
https://doi.org/10.1182/blood.V130.Suppl_1.5229.5229
Published: 2017